It’s been more than three years since DBV Technologies’ peanuty allergy therapy was rejected for FDA approval, but the company thinks it now has a clear route to market with its patch product ...

By mid-August, the Commission could recommend that the FDA restrict use or revoke the medications’ approval for children. For any of that to happen, “there’s a statutory process” outlined ...

Amphastar and its subsidiaries are committed to working closely with the FDA and other stakeholders to tackle drug supply issues and ensure that essential medications are available to patients ...

Published in JAMA Network Open, the study found that less than half of Medicaid plans cover all four of the FDA-approved medications, which include acamprosate, disulfiram, and oral and injectable ...